# Livdelzi® (seladelpar) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/seladelpar

> The FDA approved Livdelzi® (seladelpar), sponsored by GILEAD SCIENCES, INC. (GILD), on August 14, 2024 for to treat primary biliary cholangitis (PBC).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is Livdelzi® (seladelpar) FDA approved?

Yes. The FDA approved Livdelzi® (seladelpar), sponsored by GILEAD SCIENCES, INC. (GILD), on August 14, 2024 for to treat primary biliary cholangitis (PBC). FDA novel drug approvals: "Livdelzi | seladelpar | 8/14/2024 | To treat primary biliary cholangitis (PBC)Drug Trials Snapshot" [Calendar and source filings](https://sec-api.dev/pdufa/seladelpar)

Source: FDA novel drug approvals, https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024 (retrieved 2026-11-16). Last confirmed 2026-11-16T22:20:01.192Z. Cite: https://sec-api.dev/pdufa/seladelpar#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | Livdelzi® (seladelpar) |
| Codes | MBX-8025 |
| Sponsor | GILEAD SCIENCES, INC. (GILD) https://sec-api.dev/companies/gild/catalysts |
| Indications | To treat primary biliary cholangitis (PBC), [Primary Biliary Cholangitis](https://sec-api.dev/indications/primary-biliary-cholangitis), [Primary Biliary Cirrhosis](https://sec-api.dev/indications/primary-biliary-cirrhosis) |
| Modality |  |
| FDA designations | accelerated, priority review |

## Timeline

### August 14, 2024: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: To treat primary biliary cholangitis (PBC).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA novel drug approvals: "Livdelzi | seladelpar | 8/14/2024 | To treat primary biliary cholangitis (PBC)Drug Trials Snapshot" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024
- openFDA Drugs@FDA: "NDA217899 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20240814, review_priority PRIORITY; sponsor_name GILEAD SCIENCES INC; product LIVDELZI (SELADELPAR LYSINE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217899%22

### May 6, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Primary Biliary Cholangitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06060665 (Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-05-06 (ACTUAL); Lead Sponsor Gilead Sciences." https://clinicaltrials.gov/study/NCT06060665

### November 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Primary Biliary Cirrhosis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03301506 (Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-11 (ESTIMATED); Lead Sponsor Gilead Sciences." https://clinicaltrials.gov/study/NCT03301506

### Nov 2028 to Feb 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Primary Biliary Cirrhosis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03301506 (Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-11 (ESTIMATED); Lead Sponsor Gilead Sciences." https://clinicaltrials.gov/study/NCT03301506

### December 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Primary Biliary Cholangitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07841977 (Study of Seladelpar and Cilofexor in Participants With Primary Biliary Cholangitis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-12 (ESTIMATED); Lead Sponsor Gilead Sciences." https://clinicaltrials.gov/study/NCT07841977

### Dec 2028 to Mar 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Primary Biliary Cholangitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07841977 (Study of Seladelpar and Cilofexor in Participants With Primary Biliary Cholangitis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-12 (ESTIMATED); Lead Sponsor Gilead Sciences." https://clinicaltrials.gov/study/NCT07841977

### August 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Primary Biliary Cholangitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06051617 (Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-08 (ESTIMATED); Lead Sponsor Gilead Sciences." https://clinicaltrials.gov/study/NCT06051617

### Aug to Nov 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Primary Biliary Cholangitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06051617 (Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-08 (ESTIMATED); Lead Sponsor Gilead Sciences." https://clinicaltrials.gov/study/NCT06051617

## Same indication

- [Volixibat](https://sec-api.dev/pdufa/volixibat) (MIRM)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/seladelpar.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Livdelzi® (seladelpar) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/seladelpar

```bibtex
@misc{secapidev_pdufa_seladelpar_20261116,
  title        = {Livdelzi® (seladelpar) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/seladelpar}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_seladelpar_20261116","title":"Livdelzi® (seladelpar) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/seladelpar","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
